Washington DC - June 3, 2020 - The COPD Foundation team and Board of Directors are deeply troubled by the systemic injustice and discrimination present in our society. We join the country in mourning the unnecessary loss of life and denouncing the racist acts of violence faced by African American communities for decades. Our mission includes improving the lives of those affected by COPD, a mission that requires we understand, acknowledge, and address the unique barriers to achieving good health and well-being faced by communities of color and others adversely impacted by COPD.
We believe every life and every breath is a treasure that we must collectively work to protect. In the U.S. If you are black with COPD, you are more likely to end up in the emergency room and in the hospital, quality of life is worse and progress seen by many groups is absent. We recognize this is just a snapshot of the overall health disparities that exist, and we must commit to addressing them as just one step to fighting racism, violence, and institutional discrimination that has plagued our country for too long.
Now is the time to commit to productive action, and we will do more to listen and learn how our efforts can evolve and contribute to a more just society and more equitable health outcomes and then put these learnings into action throughout our advocacy, education, and research efforts.
WASHINGTON, DC—March 27, 2020 - In this time of great need, many companies are working around the clock to find solutions to the COVID-19 crisis. One of the COPD Foundation’s valued partners, Grifols, has announced the formation of a partnership with several U.S. government agencies to undertake clinical studies to determine if plasma from convalescent COVID-19 patients can lead to a potential treatment for the disease.
This innovative private-public partnership has the ability to expedite the development process and hopefully bring effective treatments to the market in a timely manner. This is just one of several projects Grifols is working on that will help nations around the world address this pandemic.
You can read the official Grifols statement on their partnership by clicking here.
The COPD Foundation is pleased to announce the publication of exciting data about the COPD Assessment Test (CAT) in the American Journal of Respiratory and Critical Care, a scientific journal published by the American Thoracic Society.
The manuscript, entitled "Clinical Development and Research Applications of the COPD Assessment Test (CAT)", was a result of the COPD Biomarker Qualification Consortium’s (CBQC) work. It highlights the importance of the CAT as a clinical outcome assessment tool as beneficial both in clinical practice and in research applications.
“This achievement demonstrates the power of patient-led collaborations in paving the road to improved disease management,” said Ruth Tal-Singer, Scientific Strategy Advisor at the COPD Foundation and former Industry Chair of the CBQC.
The CAT was developed by a multidisciplinary group of international experts in COPD as a short, easy-to-use (paper or digital) tool for patients, researchers and healthcar1e providers to assess symptoms and impact of the disease as described on the CAT website (www.catestonline.org). The CBQC experts believe that the CAT is a well-established, easy-to-use tool for the management of patients with COPD and that it is a useful outcome measure for the assessment of quality of life and disease burden in clinical trials.
Washington, DC - Dec. 3, 2019 – The COPD Foundation is pleased to announce that Olympus Medical Systems Group, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, recently joined as a member of the Corporate Partner Program. The COPD Foundation began the corporate partners program in 2016 as a way to standardize the way in which we interact with external, corporate stakeholders with the shared mission of accelerating research, pioneering research and improving the lives of all individuals affected by chronic obstructive pulmonary disease (COPD).
In December 2018, Olympus received approval from the Federal Drug Administration (FDA) for its Spiration Valve® System (SVS), intended for patients with severe emphysema. The valves are placed bronchoscopically in targeted airways of the lungs and, once in place, redirect air from diseased parts of the lungs to healthier areas, allowing the healthier lung tissue to expand and function more efficiently.
The primary results of the randomized clinical trial, entitled “Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve® System (EMPROVE): A Multicenter, Open-Label, Randomized, Controlled Trial” were measured six months after treatment and showed that SVS brings many benefits to patients, including improved lung function, target lobe volume reduction, decreased hyperinflation, a reduction in shortness of breath and an overall improvement in their quality of life. The study continued to follow patients and has now showed that improvement in measures important to patients such as lung function, shortness of breath and quality of life are durable through twelve months.
WASHINGTON, DC--Research published yesterday suggests that we may be able to finally find a way to slow disease progression and provide preventative measures for the first time to individuals at risk of developing the 4th leading cause of death in the United States—chronic obstructive pulmonary disease (COPD).
In a bold proposal that challenges decades-old criteria, the new research analysis—published in the peer-reviewed Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation—proposes to expand the criteria by which smokers are diagnosed with COPD which affects an estimated 30 million individuals in the U.S. alone (15 million diagnosed, another 15 million estimated to be undiagnosed with the disease).
Using the new criteria proposed in the published article would enable treatment to be provided earlier to slow or halt disease progression before disability or irreversible lung structural changes occurs. This new proposal comes from the COPD Genetic Epidemiology (COPDGene) study—a 21-center study of 10,000 individuals supported by the National Institutes of Health and begun in 2007.
WASHINGTON, DC, October 25, 2019— The COPD Foundation is pleased to announce that Ruth Tal-Singer, Ph.D., has joined the Foundation as a consultant in the role of Scientific Strategy Advisor. Ms. Tal-Singer is an internationally recognized expert and leader in the field of respiratory care. Her appointment became official as of October 21, 2019.
"We are so very excited that Ruth is joining the team. Ruth's deep expertise and commitment to the COPD community is so very impactful,” said Corinne Costa Davis, Chief Executive Officer of the COPD Foundation.
Prior to joining the COPD Foundation, Ms. Tal-Singer was Vice President of Medical Innovation (Galaxy) R&D Value Evidence & Outcomes and Senior Fellow at GSK Pharmaceuticals. During her career with GSK, she led many projects that resulted in new and innovative treatments for COPD.
Washington, DC—October 21, 2019 - The COPD Foundation is pleased to announce that we have launched a new version of our popular Pocket Consultant Guide (PCG) mobile app featuring a track for patients and caregivers. The PCG was originally designed as a convenient reference card for healthcare providers. The mobile version was launched in 2013 and updated in 2018. Immediately after the updated app was launched, our team began thinking of ways to improve the patient experience through a mobile app.
"Since 2007 the COPD Foundation has distributed more than 800,000 pocket consultant cards to providers around the country in hope of improving COPD care. Several years ago, the Foundation updated our free app providing a more interactive service including inhaler videos. We believe the launch of the newest version represents another important step to improving care. This new version includes a patient track with an interactive daily action plan, activity monitoring, and exercise videos. Together we can make a difference!" – Dr. Byron Thomashow, Chief Medical Officer, COPD Foundation
The newest version of the app, now available on the App Store and Google Play, has several exciting new features, including the introduction of a patient and caregiver track designed to improve disease management and communication with a patient’s healthcare team. Some of the features of the patient track include:
Study shows individuals with COPD-CAP often require weeks to recover, resulting in missed work and participation in usual activities.
Washington, DC – February 4, 2019 – According to a new study posted online in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation and conducted by the COPD Foundation in collaboration with and funded by Pfizer Inc., community-acquired pneumonia (CAP), which carries a high morbidity and economic burden worldwide, is even more physically and economically devastating to the vulnerable population of individuals with chronic obstructive pulmonary disease (COPD). CAP is a common but serious lung infection that can be caused by bacterial or viral pathogens including Streptococcus pneumoniae, influenza or rhinovirus.
COPD across America – How is your state is doing?
WASHINGTON, D.C. – November 30, 2018 – The COPD Foundation is pleased to announce the results of a landmark effort that examines the burden of COPD across America. The “COPD in the United States” project looks at COPD at the state level, identifying differences across states, regions and data points, to inform public health and policy decision-making.
COPD affects an estimated 30 million Americans but, up until now, little has been known about how one state compares to another. With the addition in 2011 of a COPD question to the Centers for Disease Control and Prevention’s Behavioral Risk Factor Surveillance System (BRFSS), the nation’s largest public health survey, more actionable information has been collected. State level data also exists to highlight the healthcare services individuals with COPD use, other conditions people with COPD may have and how different groups of people with COPD are affected.
Just collecting data isn’t enough, though, as it often sits in fragmented databases, is not analyzed or available for advocates, public health and policy decision-makers. With this project, the COPD Foundation aims to change that.
COPD Pocket Consultant Guide App now available for both iOS and Android
WASHINGTON, D.C. - November 5, 2018 –The COPD Foundation is excited to announce the launch of the COPD Pocket Consultant Guide (PCG) app for healthcare providers. The app, designed to support the treatment and management of COPD, is now available for both iOS and Android. To download the new COPD PCG app, click here.
Key features of the COPD PCG app include an updated therapy chart including the latest medications for COPD, inhaler instruction videos, depression and anxiety screeners, links to COPD Foundation resources and more.
Additional features, such as the Fletcher-Peto Impact of Smoking graph and lung volume reduction options, are included in the app as well as links to PRAXIS (the COPD Foundation’s online hub for healthcare providers), the Journal of the COPD Foundation and the National Heart, Lung and Blood Institute’s COPD National Action Plan.
WASHINGTON, D.C. - November 1, 2018 - The COPD Foundation is excited to celebrate COPD Awareness Month, an internationally recognized event held annually in November to enhance awareness of chronic obstructive pulmonary disease (COPD).
The COPD Foundation’s theme this year is “Hope and Inspiration,” which highlights the organization’s efforts to connect with COPD patients and remind them that COPD does not define them. It also aims to raise public awareness about the disease and showcase the many tools available to patients on their journey while encouraging them and their loved ones to take control of their COPD by learning more about their disease.
A number of activities have been designed to recognize patients, caregivers, friends, family members and healthcare providers impacted by COPD. These include:
COPD Foundation Announces Board of Directors Changes
Appointments Reflect Continued Focus on Advancing Thought Leadership in Respiratory Diseases
Washington, DC– September 7, 2018 – The COPD Foundation today announced the appointment of Byron M. Thomashow, MD, to the newly created position of chief medical officer. In addition to helping found the COPD Foundation, Dr. Thomashow, served as the chairman of the board since 2004. Michael P. Mayer, who recently served as the chairman of the human resources and finance committees for the COPD Foundation Board, has been appointed the Foundation’s newest chair.
Dr. Thomashow is a Professor of Medicine at the Columbia University Medical Center, an Attending Physician at the New York-Presbyterian Hospital and Medical Director of the Jo-Ann LeBuhn Center for Chest Disease on the Columbia campus. He was a member of the steering committee and the co-primary investigator at the Columbia site for the National Emphysema Treatment Trial and has been and remains actively involved in multiple national clinical research projects.